Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

Amy E. DeZern, Marianna Zahurak, Heather J. Symons, Kenneth R. Cooke, Carol Ann Huff, Tania Jain, Lode J. Swinnen, Philip H. Imus, Nina D. Wagner-Johnston, Richard F. Ambinder, Mark Levis, Leo Luznik, Javier Bolaños-Meade, Ephraim J. Fuchs, Richard J. Jones, Robert A. Brodsky

Blood (2023) 141 (25): 3031–3038.

https://doi.org/10.1182/blood.2023020435

Published: 2023

Includes: Supplemental data

Journal Articles

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Blood (2022) 140 (Supplement 1): 4813–4815.

https://doi.org/10.1182/blood-2022-171038

Published: 2022

Journal Articles

Allogeneic Blood or Marrow Transplantation (alloBMT) Using Haploidentical Grandchildren Donors and Post-Transplant Cyclophosphamide (PTCy) -Based Gvhd Prophylaxis

Yosra M. Aljawai, Hua-Ling Tsai, Ravi Varadhan, Richard J. Jones, Philip H. Imus

Blood (2022) 140 (Supplement 1): 4721–4722.

https://doi.org/10.1182/blood-2022-169028

Published: 2022

Journal Articles

CD38 Is a Key Regulator of Tumor Growth By Modulating the Metabolic Signature of Malignant Plasma Cells

Ruxandra Maria Irimia, Margo Brooke Gerke, Maya Thakar, Zhihong Ren, Eric Helmenstine, Philip H. Imus, Gabriel Ghiaur, Robert Leone, Christian B. Gocke

Blood (2021) 138 (Supplement 1): 2652.

https://doi.org/10.1182/blood-2021-148693

Published: 2021

Journal Articles

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Blood (2021) 138 (Supplement 1): 1846.

https://doi.org/10.1182/blood-2021-153750

Published: 2021

Journal Articles

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141294

Published: 2020

Journal Articles

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-141264

Published: 2020

Journal Articles

Deep Learning for Distinguishing Morphological Features of Acute Promyelocytic Leukemia

John-William Sidhom, MSc, Ingharan J Siddarthan, Bo-Shiun Lai, PhD, Adam Luo, Bryan Hambley, MD, Jennifer Bynum, MD, Amy S. Duffield, MD PhD, Michael B. Streiff, MD, Alison R. Moliterno, MD, Philip H. Imus, MD, Christian B. Gocke, MD PhD, Lukasz P. Gondek, MDPhD, Amy E. DeZern, MD, Alexander S Baras, MDPhD, Thomas S. Kickler, MD, Mark Levis, MD PhD, Eugene Shenderov, MDDPhil

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-135836

Published: 2020

Journal Articles

Second Blood or Marrow Transplant (BMT) for Relapse: Mismatch Haplotype Switch May Improve Outcome

Philip H Imus, MD, August R Dietrich, MD, Amanda Blackford, ScM, Robert A. Brodsky, MD, Heather J. Symons, Kenneth Cooke, MD, Richard J Jones, MD, Javier Bolaños-Meade, MD

Blood (2016) 128 (22): 2252.

https://doi.org/10.1182/blood.V128.22.2252.2252

Published: 2016

Journal Articles

Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System Lymphoma (PCNSL)[E1F05]

Lode J. Swinnen, MBChB, Anne O'Neill, Philip H Imus, MD, Sachin Gujar, MBBS, MD, David Schiff, MD, Lawrence Kleinberg, Ranjana Advani, Erin Dunbar, MD, Dennis F. Moore, Jr., MD, Stuart Grossman, MD

Blood (2015) 126 (23): 1530.

https://doi.org/10.1182/blood.V126.23.1530.1530

Published: 2015

NARROW

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Allogeneic Blood or Marrow Transplantation (alloBMT) Using Haploidentical Grandchildren Donors and Post-Transplant Cyclophosphamide (PTCy) -Based Gvhd Prophylaxis

CD38 Is a Key Regulator of Tumor Growth By Modulating the Metabolic Signature of Malignant Plasma Cells

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Deep Learning for Distinguishing Morphological Features of Acute Promyelocytic Leukemia

Second Blood or Marrow Transplant (BMT) for Relapse: Mismatch Haplotype Switch May Improve Outcome

Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System Lymphoma (PCNSL)[E1F05]

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only